Filtered By:
Condition: Atrial Fibrillation
Management: Health Insurance

This page shows you your search results in order of relevance. This is page number 18.

Order by Relevance | Date

Total 264 results found since Jan 2013.

Predicting Hospital Readmissions from Health Insurance Claims Data: A Modeling Study Targeting Potentially Inappropriate Prescribing
CONCLUSION: PIP successfully predicted readmissions for most diseases, opening the possibility for interventions to improve these modifiable risk factors. Machine-learning methods appear promising for future modeling of PIP predictors in complex older patients with many underlying diseases.PMID:35144291 | DOI:10.1055/s-0042-1742671
Source: Methods of Information in Medicine - February 10, 2022 Category: Information Technology Authors: Alexander Gerharz Carmen Ruff Lucas Wirbka Felicitas Stoll Walter E Haefeli Andreas Groll Andreas D Meid Source Type: research

Comparative effectiveness and safety of different combinations of antithrombotic regimens in atrial fibrillation patients with stent insertions
This study aims to compare the risks of major adverse cardiac events (MACEs), including cardiovascular death, myocardial infarction, ischemic stroke and transient ischemic attack, and major bleeding across different antithrombotic regimens in Asian atrial fibrillation (AF) patients with stent insertions. We conducted a retrospective cohort study using Taiwan's National Health Insurance Research Database and National Mortality Registry. A total of 10,208 nonvalvular AF patients who had undergone percutaneous coronary intervention (PCI) with stents for the first time in 2007-2017 were identified. Most patients (68.4%) were p...
Source: Clinical Pharmacology and Therapeutics - June 9, 2022 Category: Drugs & Pharmacology Authors: Han-Hsin Chueh Shih-Tsung Huang Shang-Hung Chang Shin-Yi Lin Fei-Yuan Hsiao Source Type: research

Effect of Sodium-Glucose Cotransporter Inhibitors on Major Adverse Cardiovascular Events and Hospitalization for Heart Failure in Patients With Type 2 Diabetes Mellitus and Atrial Fibrillation
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to lower cardiovascular morbidity and mortality in patients with type 2 diabetes mellitus (T2DM) and high cardiovascular risks. Here, we aimed to evaluate the effect of SGLT2 inhibitors on major adverse cardiovascular events (MACE), a composite of cardiovascular mortality, myocardial infarction, or ischemic stroke and hospitalization for heart failure in patients with T2DM and atrial fibrillation (AF). Using the Korean National Health Insurance Service database, we identified 40,268 patients with T2DM and AF who were newly prescribed oral hypoglycemic drugs ...
Source: The American Journal of Cardiology - July 7, 2022 Category: Cardiology Authors: Chang Hee Kwon, Ye-Jee Kim, Min-Ju Kim, Myung-Jin Cha, Min Soo Cho, Gi-Byoung Nam, Kee-Joon Choi, Jun Kim Source Type: research

Association of changes in cardiovascular health levels with incident cardiovascular events and mortality in patients with atrial fibrillation
ConclusionsImproving CVH levels and maintaining high CVH levels after AF diagnosis is associated with lower risks of subsequent cardiovascular events and mortality.Graphical abstract
Source: Clinical Research in Cardiology - July 13, 2022 Category: Cardiology Source Type: research

IJERPH, Vol. 19, Pages 12916: Impact of Integrating Machine Learning in Comparative Effectiveness Research of Oral Anticoagulants in Patients with Atrial Fibrillation
Suh We aimed to compare the ability to balance baseline covariates and explore the impact of residual confounding between conventional and machine learning approaches to derive propensity scores (PS). The Health Insurance Review and Assessment Service database (January 2012–September 2019) was used. Patients with atrial fibrillation (AF) who initiated oral anticoagulants during July 2015–September 2018 were included. The outcome of interest was stroke/systemic embolism. To estimate PS, we used a logistic regression model (i.e., a conventional approach) and a generalized boosted model (GBM) w...
Source: International Journal of Environmental Research and Public Health - October 9, 2022 Category: Environmental Health Authors: Sola Han Hae Sun Suh Tags: Article Source Type: research

Vitamin-K-antagonist phenprocoumon versus direct oral anticoagulants in patients with atrial fibrillation: a real-world analysis of German claims data
Conclusions The small superiority or non-inferiority of DOACs over warfarin seen in the RCTs might not translate into relevant advantages of DOACs over phenprocoumon. To confirm the hypothesis, an RCT with phenprocoumon is needed. Next to the safety and effectiveness assessments other factors might also play a substantial role in the decision on the right OAC for stroke prevention.
Source: BMJ Open - January 2, 2023 Category: General Medicine Authors: Warkentin, L., Klohn, F., Deiters, B., Kühlein, T., Hueber, S. Tags: Open access, Pharmacology and therapeutics Source Type: research